10 results about "Immunoglobulin E" patented technology

In one aspect, the present invention relates to a pharmaceutical unit dosage composition comprising an antibody of isotype immunoglobulin E (IgE), wherein the composition comprises less than 50 mg of the IgE antibody. The pharmaceutical unit dosage compositions may be administered to a mammalian subject and find use in treating cancer, in particular, human ovarian cancers.

The present disclosure provides conjugates comprising a moiety that targets a lysosomal targeting molecule, a linker, and an antibody that specifically binds a cell surface target molecule or extracellular target molecule that is targeted for degradation.

Described herein are heteromultimeric proteins comprising at least two different polypeptide chains. The polypeptides may comprise Cε3 domain and / or Cε4 domain derived from an immunoglobulin E, and a Cγ2 and / or a Cγ3 domain derived from an immunoglobulin G. The two polypeptide chains may preferentially heterodimerize to promote formation of the heteromultimer. The two polypeptide chains may bind to two different target molecules, e.g. a cancer antigen and a T cell antigen.

The invention discloses an anti-cat IgE (Immunoglobulin E) monoclonal antibody hybridoma cell strain, a monoclonal antibody and application of the monoclonal antibody, and belongs to the fields of immunology, in-vitro diagnosis and detection technologies and hybridoma antibody preparation. A cat IgE antigen is purified through a salting-out method and column chromatography, after mice are immunized, 6B5 and 13E11 hybridoma cell strains are screened out through cell fusion, IgG type antibodies secreted by the hybridoma cells do not have cross reaction with cat IgG, EC50 values are smaller than or equal to 0.0261 and 0.0274 respectively, the titer is larger than or equal to 1: 100000, and the purity is larger than or equal to 95%. According to the present invention, the 6B5 and 13E11 antibody combination is used for colloidal gold chromatography detection, the distance between the detection line and the quality control line is optimized to 0.5 cm, the double-antibody sandwich system is constructed, the detection sensitivity reaches 0.1 ng / mL, and 8 clinical allergic cat samples are completely positive through verification; the invention breaks through the bottleneck of the traditional detection technology, provides a high-specificity and high-sensitivity cat IgE detection scheme, lays a foundation for early diagnosis and precise medical treatment of cat allergic diseases, and has remarkable clinical application value and industrial prospect.

In one embodiment, the present invention relates to an anti-HER2 immunoglobulin E (IgE) antibody for use in the treatment of tumors with low HER2 expression in a subject. In another embodiment, the present invention provides an immunoglobulin that binds to HER2.

The present application relates to the use of Lactobacillus casei GKC1 for preparing an oral composition for reducing the endotoxin content in serum. After the administration of Lactobacillus casei GKC1 to a subject with respiratory allergy, the respiratory resistance of the subject is improved, and the content of immunoglobulin E specific to allergen and the content of endotoxin in the serum of the subject are reduced, so that Lactobacillus casei GKC1 can be used as an effective component of an oral composition for reducing the endotoxin content in serum.

The present invention provides a method of selecting and preventing an IgE-related disease in a subject in need thereof, the method including: (a) selecting a subject at risk of developing an IgE-related disease; and (b) topically administering to the subject a therapeutically effective amount of a composition capable of restoring skin barrier and orally administering to the subject a therapeutically effective amount of a composition including an allergen.

The invention discloses a camel-derived nano antibody which binds to human immunoglobulin E (IgE). Specifically, the invention discloses an anti-IgE (Immunoglobulin E) specific nano antibody and a fusion protein thereof. The invention also discloses a coding sequence for coding the VHH chain of the nano antibody, a corresponding expression vector, a host cell and a method for producing the nano antibody. The nano antibody fusion protein provided by the invention has high affinity and high specificity, and can be used for diagnosing and / or treating IgE-mediated allergic diseases.

In one aspect, the present invention relates to immunoglobulin E (IgE) antibody for use in treating and / or delaying progression of cancer in a subject, wherein the antibody has a dissociation constant (Kd) for binding to a target antigen of 10 nM or less. In another aspect, immunoglobulins that bind to HER2 are provided.

In one aspect, the present invention relates to an anti-HER2 immunoglobulin E (IgE) antibody for use in the treatment of a tumor with low expression of HER2 in a subject. In another aspect, the present invention provides immunoglobulins that bind to HER2.